Multiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration

Autoimmunity Reviews

Volumn 15, Issue 3, 2016, Pages 210-220

  Patejdl, Robert ^a   Penner, Iris K ^b   Noack, Thomas K ^a   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Cogito Center for Applied Neurocognition and Neuropsychological Research ^*  (Germany)

Author keywords

Axonal loss; Brain atrophy; Cytokine mediated sickness behavior; Fatigue; Multiple sclerosis; Neurodegeneration; Neuroinflammation

Indexed keywords

CYTOKINE;

AUTOIMMUNITY; AXONAL INJURY; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DEMYELINATION; FATIGUE; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROENDOCRINE DISEASE; NONHUMAN; REVIEW; ANIMAL; COMPLICATION; IMMUNOLOGY; NERVE CELL;

ANIMALS; AUTOIMMUNITY; CYTOKINES; FATIGUE; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; NEURONS;

EID: 84958858103     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.11.005     Document Type: Review

References (155)

1. Zettl U.K., Stuve O., Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 2012, 11:167-173.
2. Stuke K., Flachenecker P., Zettl U.K., Elias W.G., Freidel M., Haas J., et al. Symptomatology of MS: results from the German MS Registry. J Neurol 2009, 256:1932-1935.
3. Nagaraj K., Taly A.B., Gupta A., Prasad C., Christopher R. Prevalence of fatigue in patients with multiple sclerosis and its effect on the quality of life. J Neurosci Rural Pract 2013, 4:278-282.
4. Iriarte J., Subira M.L., Castro P. Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors. Mult Scler 2000, 6:124-130.
5. Kos D., Kerckhofs E., Nagels G., D'hooghe M.B., Ilsbroukx S. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair 2008, 22:91-100.
6. Kister I., Bacon T.E., Chamot E., Salter A.R., Cutter G.R., Kalina J.T., et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013, 15:146-158.
7. Runia T.F., Jafari N., Siepman Dorine A.M., Hintzen R.Q. Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry 2015, 86:543-546.
8. Mills R.J., Young C.A. A medical definition of fatigue in multiple sclerosis. QJM 2008, 101:49-60.
9. Feinstein A. Is there a cognitive signature for multiple sclerosis-related fatigue?. Mult Scler 2015, 21:353-354.
10. Penner I.K., Raselli C., Stocklin M., Opwis K., Kappos L., Calabrese P. The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 2009, 15:1509-1517.
11. Fisk J.D., Pontefract A., Ritvo P.G., Archibald C.J., Murray T.J. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994, 21:9-14.
12. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121-1123.
13. Dahl O., Stordal E., Lydersen S., Midgard R. Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trondelag County, Norway. Mult Scler 2009, 15:1495-1501.
14. Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983, 67:361-370.
15. Bonnier G., Roche A., Romascano D., Simioni S., Meskaldji D., Rotzinger D., et al. Advanced MRI unravels the nature of tissue alterations in early multiple sclerosis. Ann Clin Transl Neurol 2014, 1:423-432.
16. Criste G., Trapp B., Dutta R. Axonal loss in multiple sclerosis: causes and mechanisms. Handb Clin Neurol 2014, 122:101-113.
17. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120(Pt 3):393-399.
18. Fu L., Matthews P.M., de Stefano N., Worsley K.J., Narayanan S., Francis G.S., et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998, 121(Pt 1):103-113.
19. Filippi M., Valsasina P., Rocca M. Magnetic resonance imaging of grey matter damage in people with MS. Int MS J 2007, 14:12-21.
20. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Bruck W., Rauschka H., Bergmann M., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
21. Zivadinov R., Tekwe C., Bergsland N., Dolezal O., Havrdova E., Krasensky J., et al. Bimonthly evolution of cortical atrophy in early relapsing-remitting multiple sclerosis over 2 years: a longitudinal study. Mult Scler Int 2013, 2013:231345.
22. Papadopoulou A., Muller-Lenke N., Naegelin Y., Kalt G., Bendfeldt K., Kuster P., et al. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. Mult Scler 2013, 19:1290-1296.
23. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
24. Charcot M. Histologie de la sclerose en plaques. Gaz Hop 1868, 151:554-558.
25. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
26. Smith K.J. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol 2007, 17:230-242.
27. Skulina C., Schmidt S., Dornmair K., Babbe H., Roers A., Rajewsky K., et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A 2004, 101:2428-2433.
28. Vidaurre O.G., Haines J.D., Katz Sand I., Adula K.P., Huynh J.L., McGraw C.A., et al. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain 2014, 137:2271-2286.
29. Haider L., Fischer M.T., Frischer J.M., Bauer J., Hoftberger R., Botond G., et al. Oxidative damage in multiple sclerosis lesions. Brain 2011, 134:1914-1924.
30. Fraussen J., Claes N., de Bock L., Somers V. Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 2014, 13:1126-1137.
31. Codella M., Rocca M.A., Colombo B., Rossi P., Comi G., Filippi M. A preliminary study of magnetization transfer and diffusion tensor MRI of multiple sclerosis patients with fatigue. J Neurol 2002, 249:535-537.
32. van der Werf S.P., Jongen P.J., Lycklama a Nijeholt G.J., Barkhof F., Hommes O.R., Bleijenberg G. Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. J Neurol Sci 1998, 160:164-170.
33. Bakshi R., Miletich R.S., Henschel K., Shaikh Z.A., Janardhan V., Wasay M., et al. Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology 1999, 53:1151-1153.
34. Rocca M.A., Parisi L., Pagani E., Copetti M., Rodegher M., Colombo B., et al. Regional but not global brain damage contributes to fatigue in multiple sclerosis. Radiology 2014, 273:511-520.
35. Tedeschi G., Dinacci D., Lavorgna L., Prinster A., Savettieri G., Quattrone A., et al. Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. J Neurol Sci 2007, 263:15-19.
36. Nygaard G.O., Walhovd K.B., Sowa P., Chepkoech J., Bjornerud A., Due-Tonnessen P., et al. Cortical thickness and surface area relate to specific symptoms in early relapsing-remitting multiple sclerosis. Mult Scler 2015, 21:402-414.
37. Pellicano C., Gallo A., Li X., Ikonomidou V.N., Evangelou I.E., Ohayon J.M., et al. Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. Arch Neurol 2010, 67:447-453.
38. Gobbi C., Rocca M.A., Riccitelli G., Pagani E., Messina R., Preziosa P., et al. Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Mult Scler 2014, 20:192-201.
39. Calabrese M., Rinaldi F., Grossi P., Mattisi I., Bernardi V., Favaretto A., et al. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult Scler 2010, 16:1220-1228.
40. Bester M., Lazar M., Petracca M., Babb J.S., Herbert J., Grossman R.I., et al. Tract-specific white matter correlates of fatigue and cognitive impairment in benign multiple sclerosis. J Neurol Sci 2013, 330:61-66.
41. Cruz Gómez Álvaro Javier, Ventura Campos N., Belenguer A., Ávila C., Forn C., He Y. Regional brain atrophy and functional connectivity changes related to fatigue in multiple sclerosis. PLoS One 2013, 8:e77914.
42. Sepulcre J., Masdeu J.C., Goni J., Arrondo G., Velez de Mendizabal N., Bejarano B., et al. Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler 2009, 15:337-344.
43. Pardini M., Bonzano L., Mancardi G.L., Roccatagliata L. Frontal networks play a role in fatigue perception in multiple sclerosis. Behav Neurosci 2010, 124:329-336.
44. Reddy H., Narayanan S., Arnoutelis R., Jenkinson M., Antel J., Matthews P.M., et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 2000, 123(Pt 11):2314-2320.
45. Rocca M., Absinta M., Valsasina P., Copetti M., Caputo D., Comi G., et al. Abnormal cervical cord function contributes to fatigue in multiple sclerosis. Mult Scler J 2012, 18:1552-1559.
46. Niepel G., Bibani R.H., Vilisaar J., Langley R.W., Bradshaw C.M., Szabadi E., et al. Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil. Neuropharmacology 2013, 64:380-388.
47. Hanken K., Eling P., Hildebrandt H. Is there a cognitive signature for MS-related fatigue?. Mult Scler 2015, 21:376-381.
48. Ng A.V., Miller R.G., Kent-Braun J.A. Central motor drive is increased during voluntary muscle contractions in multiple sclerosis. Muscle Nerve 1997, 20:1213-1218.
49. Scheidegger O., Kamm C.P., Humpert S.J., Rosler K.M. Corticospinal output during muscular fatigue differs in multiple sclerosis patients compared to healthy controls. Mult Scler 2012, 18:1500-1506.
50. Specogna I., Casagrande F., Lorusso A., Catalan M., Gorian A., Zugna L., et al. Functional MRI during the execution of a motor task in patients with multiple sclerosis and fatigue. Radiol Med 2012, 117:1398-1407.
51. Wilting J., Rolfsnes H.O., Zimmermann H., Behrens M., Fleischer V., Zipp F., et al. Structural correlates for fatigue in early relapsing remitting multiple sclerosis. Eur Radiol 2015, (Epub ahead of print). 10.1007/s00330-015-3857-2.
52. Wang Z., Dai Z., Gong G., Zhou C., He Y. Understanding structural-functional relationships in the human brain: a large-scale network perspective. Neuroscientist 2015, 21:290-305.
53. van den Heuvel Martijn P., Sporns O. Rich-club organization of the human connectome. J Neurosci 2011, 31:15775-15786.
54. Filippi M., Rocca M.A., Colombo B., Falini A., Codella M., Scotti G., et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 2002, 15:559-567.
55. Roelcke U., Kappos L., Lechner-Scott J., Brunnschweiler H., Huber S., Ammann W., et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997, 48:1566-1571.
56. Minagar A., Barnett M.H., Benedict Ralph H.B., Pelletier D., Pirko I., Sahraian M.A., et al. The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology 2013, 80:210-219.
57. Evans W.J., Lambert C.P. Physiological basis of fatigue. Am J Phys Med Rehabil 2007, 86:S29-S46.
58. Vollmer-Conna U., Lloyd A., Hickie I., Wakefield D. Chronic fatigue syndrome: an immunological perspective. Aust N Z J Psychiatry 1998, 32:523-527.
59. Morris G., Berk M., Walder K., Maes M. Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med 2015, 13:28.
60. Anderson G., Berk M., Maes M. Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatr Scand 2014, 129:83-97.
61. Schoonheim M.M., Hulst H.E., Brandt R.B., Strik M., Wink A.M., Uitdehaag Bernard M.J., et al. Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. Neurology 2015, 84:776-783.
62. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002, 25:154-159.
63. Hart B.L. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988, 12:123-137.
64. Cao C., Matsumura K., Yamagata K., Watanabe Y. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain. Am J Physiol 1997, 272:R1712-R1725.
65. Vidensky S., Zhang Y., Hand T., Goellner J., Shaffer A., Isakson P., et al. Neuronal overexpression of COX-2 results in dominant production of PGE2 and altered fever response. Neuromolecular Med 2003, 3:15-28.
66. Dantzer R., Konsman J.P., Bluthe R.M., Kelley K.W. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent?. Auton Neurosci 2000, 85:60-65.
67. D'Ambrosio A., Pontecorvo S., Colasanti T., Zamboni S., Francia A., Margutti P. Peripheral blood biomarkers in multiple sclerosis. Autoimmun Rev 2015, 14:1097-1110.
68. Fitzner B., Hecker M., Zettl U.K. Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. Autoimmun Rev 2015, 14:903-913.
69. Konsman J.P., Kelley K., Dantzer R. Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1beta and inducible nitric oxide synthase in rat brain. Neuroscience 1999, 89:535-548.
70. Ericsson A., Liu C., Hart R.P., Sawchenko P.E. Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J Comp Neurol 1995, 361:681-698.
71. Maier S.F., Watkins L.R. Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res 1995, 695:279-282.
72. Rudick R.A., Barna B.P. Serum interleukin 2 and soluble interleukin 2 receptor in patients with multiple sclerosis who are experiencing severe fatigue. Arch Neurol 1990, 47:254-255.
73. Giovannoni G., Thompson A.J., Miller D.H., Thompson E.J. Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology 2001, 57:676-681.
74. Kraus J., Oschmann P., Engelhardt B., Schiel C., Hornig C., Bauer R., et al. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand 1998, 98:102-109.
75. Heesen C., Koehler G., Gross R., Tessmer W., Schulz K., Gold S.M. Altered cytokine responses to cognitive stress in multiple sclerosis patients with fatigue. Mult Scler 2005, 11:51-57.
76. Flachenecker P., Bihler I., Weber F., Gottschalk M., Toyka K.V., Rieckmann P. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler 2004, 10:165-169.
77. Heesen C., Nawrath L., Reich C., Bauer N., Schulz K., Gold S.M. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?. J Neurol Neurosurg Psychiatry 2006, 77:34-39.
78. Malekzadeh A., Van de Geer-Peeters Wietske, de Groot V., Teunissen C.E., Beckerman H. Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines?. Dis Markers 2015, 2015:758314.
79. Flachenecker P., Meissner H. Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment. Mult Scler 2008, 14:274-277.
80. Comi G., Leocani L., Rossi P., Colombo B. Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol 2001, 248:174-179.
81. Lindquist S., Hassinger S., Lindquist J.A., Sailer M. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Mult Scler 2011, 17:851-866.
82. Nijs J., Nees A., Paul L., de Kooning M., Ickmans K., Meeus M., et al. Altered immune response to exercise in patients with chronic fatigue syndrome/myalgic encephalomyelitis: a systematic literature review. Exerc Immunol Rev 2014, 20:94-116.
83. Lorusso L., Mikhaylova S.V., Capelli E., Ferrari D., Ngonga G.K., Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8:287-291.
84. Castellano V., Patel D.I., White L.J. Cytokine responses to acute and chronic exercise in multiple sclerosis. J Appl Physiol 2008, 104:1697-1702.
85. White A.T., Light A.R., Hughen R.W., Vanhaitsma T.A., Light K.C. Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls. Psychosom Med 2012, 74:46-54.
86. Golzari Z., Shabkhiz F., Soudi S., Kordi M.R., Hashemi S.M. Combined exercise training reduces IFN-gamma and IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis. Int Immunopharmacol 2010, 10:1415-1419.
87. White L.J., Castellano V., Coy Mc, Sean C. Cytokine responses to resistance training in people with multiple sclerosis. J Sports Sci 2006, 24:911-914.
88. Kjolhede T., Dalgas U., Gade A.B., Bjerre M., Stenager E., Petersen T., et al. Acute and chronic cytokine responses to resistance exercise and training in people with multiple sclerosis. Scand J Med Sci Sports 2015, (Epub ahead of print).
89. Perez-Aso M., Feig J.L., Mediero A., Cronstein B.N. Adenosine A2A receptor and TNF-alpha regulate the circadian machinery of the human monocytic THP-1 cells. Inflammation 2013, 36:152-162.
90. Yoshida K., Hashimoto T., Sakai Y., Hashiramoto A. Involvement of the circadian rhythm and inflammatory cytokines in the pathogenesis of rheumatoid arthritis. J Immunol Res 2014, 2014:282495.
91. Kouri V., Olkkonen J., Kaivosoja E., Ainola M., Juhila J., Hovatta I., et al. Circadian timekeeping is disturbed in rheumatoid arthritis at molecular level. PLoS One 2013, 8.
92. Harbuz M. Neuroendocrine function and chronic inflammatory stress. Exp Physiol 2002, 87:519-525.
93. Zellini F., Niepel G., Tench C.R., Constantinescu C.S. Hypothalamic involvement assessed by T1 relaxation time in patients with relapsing-remitting multiple sclerosis. Mult Scler 2009, 15:1442-1449.
94. Huitinga I., Erkut Z.A., van Beurden D., Swaab D.F. Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Ann Neurol 2004, 55:37-45.
95. Then Bergh F., Kumpfel T., Trenkwalder C., Rupprecht R., Holsboer F. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology 1999, 53:772-777.
96. Michelson D., Stone L., Galliven E., Magiakou M.A., Chrousos G.P., Sternberg E.M., et al. Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function. J Clin Endocrinol Metab 1994, 79:848-853.
97. Reder A.T., Makowiec R.L., Lowy M.T. Adrenal size is increased in multiple sclerosis. Arch Neurol 1994, 51:151-154.
98. Nijhof S.L., Rutten Juliette M.T.M., Uiterwaal Cuno S.P.M., Bleijenberg G., Kimpen Jan L.L., van de Putte Elise M. The role of hypocortisolism in chronic fatigue syndrome. Psychoneuroendocrinology 2014, 42:199-206.
99. Heesen C., Gold S.M., Raji A., Wiedemann K., Schulz K. Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis. Psychoneuroendocrinology 2002, 27:505-517.
100. Gottschalk M., Kumpfel T., Flachenecker P., Uhr M., Trenkwalder C., Holsboer F., et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 2005, 62:277-280.
101. Powell Daniel J.H., Moss-Morris R., Liossi C., Schlotz W. Circadian cortisol and fatigue severity in relapsing-remitting multiple sclerosis. Psychoneuroendocrinology 2015, 56:120-131.
102. Fleming W.E., Pollak C.P. Sleep disorders in multiple sclerosis. Semin Neurol 2005, 25:64-68.
103. Strober L.B., Arnett P.A. An examination of four models predicting fatigue in multiple sclerosis. Arch Clin Neuropsychol 2005, 20:631-646.
104. Chwastiak L.A., Gibbons L.E., Ehde D.M., Sullivan M., Bowen J.D., Bombardier C.H., et al. Fatigue and psychiatric illness in a large community sample of persons with multiple sclerosis. J Psychosom Res 2005, 59:291-298.
105. Gobbi C., Rocca M., Pagani E., Riccitelli G., Pravata E., Radaelli M., et al. Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis. Mult Scler J 2014, 20:1633-1640.
106. Sternberg Z. Promoting sympathovagal balance inmultiple sclerosis; pharmacological, non-pharmacological, and surgical strategies. Autoimmun Rev 2016, 15.
107. Patti F., Amato M.P., Trojano M., Bastianello S., Tola M.R., Picconi O., et al. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Mult Scler 2011, 17:991-1001.
108. Manceau P., Latarche C., Pittion S., Edan G., de Seze J., Massart C., et al. Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis. BMC Neurol 2014, 14:215.
109. Mendozzi L., Tronci F., Garegnani M., Pugnetti L. Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: an actigraphic study. Mult Scler 2010, 16:238-247.
110. Brod S.A., Marshall G.D., Henninger E.M., Sriram S., Khan M., Wolinsky J.S. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996, 46:1633-1638.
111. Jongen P.J., Lehnick D., Sanders E., Seeldrayers P., Fredrikson S., Andersson M., et al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes 2010, 8:133.
112. Jongen P.J., Lehnick D., Koeman J., Frequin S., Heersema D., Kornips B., et al. Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study. J Neurol 2014, 261:1469-1476.
113. Ziemssen T., Hoffman J., Apfel R., Kern S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes 2008, 6:67.
114. Hadjimichael O., Vollmer T., Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 2008, 6:100.
115. Metz L.M., Patten S.B., Archibald C.J., Bakker J.I., Harris C.J., Patry D.G., et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry 2004, 75:1045-1047.
116. Yildiz M., Tettenborn B., Putzki N. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate. Eur Neurol 2011, 65:231-232.
117. Putzki N., Yaldizli O., Tettenborn B., Diener H.C. Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sci 2009, 285:109-113.
118. Svenningsson A., Falk E., Celius E.G., Fuchs S., Schreiber K., Berko S., et al. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS One 2013, 8.
119. Penner I., Sivertsdotter E.C., Celius E.G., Fuchs S., Schreiber K., Berko S., et al. Improvement in fatigue during natalizumab treatment is linked to improvement in depression and day-time sleepiness. Front Neurol 2015, 6:18.
120. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
121. Khademi M., Stol D., Olsson T., Wallstrom E. Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis. Eur J Neurol 2008, 15:309-312.
122. Comi G., O'Connor P., Montalban X., Antel J., Radue E., Karlsson G., et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010, 16:197-207.
123. Montalban X., Comi G., O'Connor P., Gold S., de Vera A., Eckert B., et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. Mult Scler 2011, 17:1341-1350.
124. Calkwood J., Cree B., Crayton H., Kantor D., Steingo B., Barbato L., et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurol 2014, 14:220.
125. Fox E., Edwards K., Burch G., Wynn D.R., LaGanke C., Crayton H., et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord 2014, 3:607-619.
126. Kappos L., Gold R., Miller D.H., Macmanus D.G., Havrdova E., Limmroth V., et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (London, England) 2008, 372:1463-1472.
127. Gold R., Giovannoni G., Phillips J.T., Fox R.J., Zhang A., Meltzer L., et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler 2015, 21:57-66.
128. Vermersch P., Czlonkowska A., Grimaldi Luigi M.E., Confavreux C., Comi G., Kappos L., et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014, 20:705-716.
129. He D., Xu Z., Dong S., Zhang H., Zhou H., Wang L., et al. Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev 2012, 12.
130. Thibault M., Havdrova E., Giovannoni G., Moargolin D.H., Kasten L., Singer B. Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: 3-year follow-up of CARE-MS II. ECTRIMS Online Libr 2014, 63751.
131. Ostberg A., Pittas F., Taylor B. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status. Intern Med J 2005, 35:382-387.
132. Vercoulen J.H., Swanink C.M., Fennis J.F., Galama J.M., van der Meer J.W., Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994, 38:383-392.
133. Colombo B., Martinelli Boneschi F., Rossi P., Rovaris M., Maderna L., Filippi M., et al. MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. J Neurol 2000, 247:506-509.
134. Derache N., Grassiot B., Mezenge F., Emmanuelle Dugue A., Desgranges B., Constans J., et al. Fatigue is associated with metabolic and density alterations of cortical and deep gray matter in Relapsing-Remitting-Multiple Sclerosis patients at the earlier stage of the disease: a PET/MR study. Mult Scler Relat Disord 2013, 2:362-369.
135. Damasceno A., Damasceno B.P., Cendes F. Atrophy of reward-related striatal structures in fatigued MS patients is independent of physical disability. Mult Scler 2015, (Epub ahead of print).
136. Andreasen A.K., Jakobsen J., Soerensen L., Andersen H., Petersen T., Bjarkam C.R., et al. Regional brain atrophy in primary fatigued patients with multiple sclerosis. Neuroimage 2010, 50:608-615.
137. Finke C., Schlichting J., Papazoglou S., Scheel M., Freing A., Soemmer C., et al. Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue. Mult Scler 2015, 21:925-934.
138. Mainero C., Faroni J., Gasperini C., Filippi M., Giugni E., Ciccarelli O., et al. Fatigue and magnetic resonance imaging activity in multiple sclerosis. J Neurol 1999, 246:454-458.
139. Tartaglia M.C., Narayanan S., Francis S.J., Santos A.C., de Stefano N., Lapierre Y., et al. The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol 2004, 61:201-207.
140. Pokryszko-Dragan A., Bladowska J., Zimny A., Slotwinski K., Zagrajek M., Gruszka E., et al. Magnetic resonance spectroscopy findings as related to fatigue and cognitive performance in multiple sclerosis patients with mild disability. J Neurol Sci 2014, 339:35-40.
141. Hartkamp A., Geenen R., Bijl M., Kruize A.A., Godaert G.L.R., Derksen R.H.W.M. Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjogren's syndrome. Ann Rheum Dis 2004, 63:1335-1337.
142. Norheim K.B., Harboe E., Goransson L.G., Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome-a double blind, randomised clinical trial. PLoS One 2012, 7.
143. Omdal R., Gunnarsson R. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis-a pilot study. Rheumatol Int 2005, 25:481-484.
144. Fragiadaki K., Tektonidou M.G., Konsta M., Chrousos G.P., Sfikakis P.P. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol 2012, 39:60-62.
145. Evers Andrea W.M., Verhoeven Elisabeth W.M., van Middendorp H., Sweep Fred C.G.J., Kraaimaat F.W., Donders A.Rogier T., et al. Does stress affect the joints? Daily stressors, stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in rheumatoid arthritis. Ann Rheum Dis 2014, 73:1683-1688.
146. Druce K.L., Jones G.T., Macfarlane G.J., Basu N. Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 2015, 54:964-971.
147. van Hoogmoed D., Fransen J., Repping-Wuts H., Spee L., Bleijenberg G., van Riel P.L.C.M. The effect of anti-TNF-alpha vs. DMARDs on fatigue in rheumatoid arthritis patients. Scand J Rheumatol 2013, 42:15-19.
148. Chauffier K., Salliot C., Berenbaum F., Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford) 2012, 51:60-68.
149. Omdal R., Mellgren S.I., Koldingsnes W., Jacobsen E.A., Husby G. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 2002, 29:482-486.
150. Fletcher M.A., Zeng X.R., Barnes Z., Levis S., Klimas N.G. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009, 7:96.
151. Pasquali L., Pecori C., Lucchesi C., LoGerfo A., Iudice A., Siciliano G., et al. Plasmatic oxidative stress biomarkers in multiple sclerosis: relation with clinical and demographic characteristics. Clin Biochem 2015, 48:19-23.
152. Norheim K.B., Jonsson G., Harboe E., Hanasand M., Goransson L., Omdal R. Oxidative stress, as measured by protein oxidation, is increased in primary Sjogren's syndrome. Free Radic Res 2012, 46:141-146.
153. Maes M., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased plasma peroxides as a marker of oxidative stress in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Sci Monit 2011, 17:SC11-SC15.
154. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett 2009, 30:715-722.
155. Richards R.S., Roberts T.K., McGregor N.R., Dunstan R.H., Butt H.L. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep 2000, 5:35-41.